[go: up one dir, main page]

FI20001750A0 - Farmaseuttisia koostumuksia - Google Patents

Farmaseuttisia koostumuksia

Info

Publication number
FI20001750A0
FI20001750A0 FI20001750A FI20001750A FI20001750A0 FI 20001750 A0 FI20001750 A0 FI 20001750A0 FI 20001750 A FI20001750 A FI 20001750A FI 20001750 A FI20001750 A FI 20001750A FI 20001750 A0 FI20001750 A0 FI 20001750A0
Authority
FI
Finland
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
FI20001750A
Other languages
English (en)
Swedish (sv)
Other versions
FI20001750L (fi
FI121365B (fi
Inventor
Joseph Richard Creekmore
Norman Afred Wiggins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI20001750(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of FI20001750A0 publication Critical patent/FI20001750A0/fi
Publication of FI20001750L publication Critical patent/FI20001750L/fi
Application granted granted Critical
Publication of FI121365B publication Critical patent/FI121365B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI20001750A 2000-01-26 2000-08-04 (E)-7-[4-(4-fluori-fenyyli)-6-isopropyyli-2-[metyyli(metyylisulfonyyli)amino]pyrimidin-5-yyli]-(3R,5S)-3,5-dihydroksi-6-hepteenihappoa käsittävä farmaseuttinen koostumus ja menetelmä sen valmistamiseksi FI121365B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions
GB0001621 2000-01-26

Publications (3)

Publication Number Publication Date
FI20001750A0 true FI20001750A0 (fi) 2000-08-04
FI20001750L FI20001750L (fi) 2001-07-27
FI121365B FI121365B (fi) 2010-10-29

Family

ID=9884259

Family Applications (3)

Application Number Title Priority Date Filing Date
FI20001749A FI111806B (fi) 2000-01-26 2000-08-04 Farmaseuttisia koostumuksia
FI20001750A FI121365B (fi) 2000-01-26 2000-08-04 (E)-7-[4-(4-fluori-fenyyli)-6-isopropyyli-2-[metyyli(metyylisulfonyyli)amino]pyrimidin-5-yyli]-(3R,5S)-3,5-dihydroksi-6-hepteenihappoa käsittävä farmaseuttinen koostumus ja menetelmä sen valmistamiseksi
FI20105657A FI121589B (fi) 2000-01-26 2010-06-10 (E)-7[4-(4-fluorifenyyli)-6-isopropyyli-2[metyyli(metyylisulfonyyli)amino]pyrimidin-5-yyli]-(3R, 5S)-3,5-dihydroksi-6-hepteenihappoa käsittävä farmaseuttinen koostumus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI20001749A FI111806B (fi) 2000-01-26 2000-08-04 Farmaseuttisia koostumuksia

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20105657A FI121589B (fi) 2000-01-26 2010-06-10 (E)-7[4-(4-fluorifenyyli)-6-isopropyyli-2[metyyli(metyylisulfonyyli)amino]pyrimidin-5-yyli]-(3R, 5S)-3,5-dihydroksi-6-hepteenihappoa käsittävä farmaseuttinen koostumus

Country Status (48)

Country Link
US (2) US6316460B1 (fi)
EP (6) EP2266540A1 (fi)
JP (3) JP3267960B2 (fi)
KR (3) KR100698333B1 (fi)
CN (3) CN1149997C (fi)
AP (2) AP1879A (fi)
AR (3) AR025055A1 (fi)
AT (3) AT412063B (fi)
AU (5) AU781269C (fi)
BE (2) BE1013414A5 (fi)
BG (4) BG65234B1 (fi)
BR (2) BR0003365A (fi)
CA (3) CA2639407C (fi)
CH (2) CH700184B1 (fi)
CL (1) CL2007001807A1 (fi)
CR (3) CR6568A (fi)
CZ (3) CZ290167B6 (fi)
DE (3) DE60001371T2 (fi)
DK (3) DK200001170A (fi)
EE (3) EE04990B1 (fi)
ES (2) ES2155043B1 (fi)
FI (3) FI111806B (fi)
FR (2) FR2795324B1 (fi)
GB (3) GB0001621D0 (fi)
HK (4) HK1048950A1 (fi)
HR (3) HRP20020097B1 (fi)
HU (2) HUP0003111A3 (fi)
IL (4) IL150513A0 (fi)
IS (3) IS1940B (fi)
IT (2) ITTO20000779A1 (fi)
ME (4) ME00202B (fi)
MY (2) MY123650A (fi)
NL (2) NL1015858C2 (fi)
NO (4) NO327675B1 (fi)
NZ (2) NZ519774A (fi)
PL (2) PL196808B1 (fi)
PT (3) PT102503B (fi)
RS (1) RS50201B (fi)
RU (2) RU2264210C2 (fi)
SE (2) SE523471C2 (fi)
SI (1) SI1223918T1 (fi)
SK (2) SK11792000A3 (fi)
TR (3) TR200201888T2 (fi)
TW (2) TWI228050B (fi)
UA (2) UA51853C2 (fi)
WO (2) WO2001054668A1 (fi)
YU (1) YU52902A (fi)
ZA (2) ZA200003998B (fi)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
IL152179A (en) † 2000-04-10 2009-06-15 Teva Pharma Stable pharmaceutical compositions containing 7-substituted-3,5- dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
WO2004016262A1 (ja) * 2002-08-12 2004-02-26 Kyowa Hakko Kogyo Co., Ltd. アミノ酸含有チュアブル錠
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
US7396927B2 (en) * 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
DK3395340T3 (da) * 2003-09-12 2019-07-15 Amgen Inc Hurtigt opløsende formulering af cinacalcet-hcl
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
PT1689723E (pt) * 2003-12-02 2011-07-06 Teva Pharma Padrão referência para a caracterização de rosuvastatina
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
TW201240679A (en) * 2004-03-12 2012-10-16 Capsugel Belgium Nv Pharmaceutical formulations
EP1755556A4 (en) * 2004-05-04 2009-09-30 Innophos Inc DIRECTLY COMPRESSIBLE TRICALCIUM PHOSPHATE
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
JP2008516890A (ja) * 2004-08-06 2008-05-22 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なフェノフィブラート製剤および関連治療方法
CA2594017C (en) * 2005-02-22 2010-04-20 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
RU2303980C2 (ru) * 2005-06-03 2007-08-10 ОАО "Щелковский витаминный завод" Лекарственная форма с антиагрегационным действием и способ ее изготовления
CN101500555A (zh) * 2005-08-04 2009-08-05 变换药品公司 包含非诺贝特和他汀的新型制剂及相关治疗方法
KR20070062996A (ko) * 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
NZ567188A (en) 2005-09-12 2011-04-29 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AU2006309826B2 (en) * 2005-10-31 2012-01-19 Kowa Co., Ltd. Pharmaceutical preparation having excellent photostability
US20090093499A1 (en) * 2005-12-20 2009-04-09 Lek Pharmaceuticals D.D. Pharmaceutical composition
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
WO2007125547A2 (en) * 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
EP2086945B1 (en) * 2006-10-09 2016-01-06 MSN Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080248115A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
EP2285353A1 (en) * 2008-01-30 2011-02-23 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
EP2298745B1 (en) 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
JP2012502883A (ja) * 2008-06-13 2012-02-02 グラクソ グループ リミテッド 医薬製剤
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
SI2309992T1 (en) * 2008-06-27 2018-03-30 Krka, Tovarna Zdravil, D.D., Novo Mesto A pharmaceutical composition comprising a statin
BRPI0822782A2 (pt) * 2008-06-27 2015-09-29 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi composição farmacêutica que compreende rosuvastatina
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
EA201270269A1 (ru) 2009-08-13 2012-09-28 Синтон Б.В. Фармацевтическая таблетка, содержащая розувастатин кальция
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
WO2012141160A1 (ja) * 2011-04-12 2012-10-18 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
EP2709592B1 (en) 2011-05-20 2017-08-16 AstraZeneca UK Limited Pharmaceutical composition of rosuvastatin calcium
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
US10952968B2 (en) * 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
KR20140111982A (ko) * 2013-03-12 2014-09-22 주식회사 엘지생명과학 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
CN107072997A (zh) * 2014-11-11 2017-08-18 盐野义制药株式会社 含有对光不稳定的药物的多层片剂
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
AU2016342374B2 (en) 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN108697649A (zh) 2015-12-08 2018-10-23 林德拉有限公司 用于胃驻留系统的几何构型
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
CN119925721A (zh) 2016-05-27 2025-05-06 林德拉治疗公司 用于胃驻留系统的材料结构
CN118766834A (zh) 2016-09-30 2024-10-15 林德拉治疗公司 用于金刚烷类药物缓释的胃驻留系统
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
WO2018227147A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
WO1990003973A1 (en) * 1988-10-06 1990-04-19 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
ES2064887T3 (es) 1990-09-13 1995-02-01 Akzo Nobel Nv Composiciones quimicas solidas estabilizadas.
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
RU2098411C1 (ru) * 1991-08-02 1997-12-10 Иституто Лусо Фармако д Италия С.п.А. Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
WO1994016693A1 (en) 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
AU725622B2 (en) * 1995-12-22 2000-10-19 Kowa Company, Ltd. Pharmaceutical composition stabilized with a basic agent
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
HUP0102260A3 (en) 1998-06-05 2002-12-28 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1253921A4 (en) 2000-01-28 2004-10-13 Merck & Co Inc TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS

Also Published As

Publication number Publication date
AU781269B2 (en) 2005-05-12
GB0019028D0 (en) 2000-09-27
AU2000264559A1 (en) 2001-08-07
FI20001750L (fi) 2001-07-27
ATA13612000A (de) 2004-02-15
MY122707A (en) 2006-04-29
CN101028268A (zh) 2007-09-05
GB2358583B (en) 2002-02-06
SE0002826D0 (sv) 2000-08-04
HK1036934A1 (en) 2002-01-25
AP1879A (en) 2008-08-14
JP4800467B2 (ja) 2011-10-26
CR6687A (es) 2005-07-18
AR023624A1 (es) 2002-09-04
EP2018853A1 (en) 2009-01-28
US6548513B1 (en) 2003-04-15
IL150513A0 (en) 2003-02-12
AR060248A2 (es) 2008-06-04
ES2171123A1 (es) 2002-08-16
HK1040936A1 (zh) 2002-06-28
NO20003967L (no) 2001-07-27
US6316460B1 (en) 2001-11-13
WO2001054668A1 (en) 2001-08-02
AP2002002409A0 (en) 2002-03-31
PL196808B1 (pl) 2008-02-29
IL147870A0 (en) 2002-08-14
CZ290167B6 (cs) 2002-06-12
IS2805B (is) 2012-09-15
HK1040936B (zh) 2010-06-11
ES2171123B1 (es) 2003-11-16
PT102504A (pt) 2001-07-31
PT102503B (pt) 2004-02-27
FI20001749L (fi) 2001-07-27
HRP20020632A2 (en) 2004-12-31
RU2264210C2 (ru) 2005-11-20
JP2001206877A (ja) 2001-07-31
DK200001171A (da) 2001-07-27
NZ531474A (en) 2007-04-27
CR6568A (es) 2004-03-05
ATE232088T1 (de) 2003-02-15
BG66159B1 (bg) 2011-09-30
NO2010005I1 (no) 2010-05-03
WO2001054669A1 (en) 2001-08-02
ITTO20000779A0 (it) 2000-08-04
HU0003111D0 (en) 2000-10-28
IS8620A (is) 2007-03-07
SK11782000A3 (sk) 2001-12-03
CZ299105B6 (cs) 2008-04-23
JP2007182452A (ja) 2007-07-19
HUP0003111A2 (hu) 2002-02-28
SE0002827D0 (sv) 2000-08-04
HRP20020632B1 (en) 2010-12-31
HUP0003110A2 (hu) 2001-05-28
GB0001621D0 (en) 2000-03-15
PL341855A1 (en) 2001-07-30
CN100528161C (zh) 2009-08-19
UA51853C2 (uk) 2002-12-16
DE60001371D1 (de) 2003-03-13
FI20105657L (fi) 2010-06-10
MY123650A (en) 2006-05-31
CL2007001807A1 (es) 2008-01-18
FI111806B (fi) 2003-09-30
FR2804025B1 (fr) 2002-08-23
AU5184200A (en) 2001-08-02
ITTO20000780A1 (it) 2000-11-04
NZ519774A (en) 2004-04-30
NO20003967D0 (no) 2000-08-04
BE1013413A3 (fr) 2001-12-04
SK283872B6 (sk) 2004-03-02
BR0003364A (pt) 2001-09-18
AU2005202392C1 (en) 2016-06-02
NO327675B1 (no) 2009-09-07
AU6580000A (en) 2001-08-07
CA2639407C (en) 2011-09-13
SE0002826L (sv) 2001-07-27
AU2005202392B2 (en) 2008-11-20
PL341853A1 (en) 2001-01-29
KR20000072135A (ko) 2000-12-05
CA2639407A1 (en) 2001-07-26
BG65234B1 (bg) 2007-09-28
IS6254A (is) 2002-01-29
GB2358582B (en) 2004-09-29
GB2358582A (en) 2001-08-01
SE0002827L (sv) 2001-07-27
ZA200003998B (en) 2000-08-14
HUP0003110A3 (en) 2003-02-28
EP1223918A1 (en) 2002-07-24
AU738074B2 (en) 2001-09-06
CN1149997C (zh) 2004-05-19
BR0003365A (pt) 2001-09-18
AR025055A1 (es) 2002-11-06
NL1015859C2 (nl) 2001-10-16
GB2358583A (en) 2001-08-01
EE04990B1 (et) 2008-04-15
CA2313783A1 (en) 2000-10-16
YU5202A (sh) 2004-12-31
FR2804025A1 (fr) 2001-07-27
EP2774609A1 (en) 2014-09-10
EE05221B1 (et) 2009-10-15
DE10038110B4 (de) 2006-06-29
BG106393A (en) 2002-07-31
EE200200411A (et) 2003-12-15
IL147870A (en) 2003-10-31
NL1015858C2 (nl) 2001-07-27
KR100388713B1 (ko) 2003-06-25
BE1013414A5 (fr) 2001-12-04
ITTO20000779A1 (it) 2002-02-04
BG106926A (bg) 2003-04-30
ZA200003997B (en) 2000-08-14
CA2315141C (en) 2009-08-18
MEP33808A (hr) 2010-10-10
RU2206324C1 (ru) 2003-06-20
PT1223918E (pt) 2003-06-30
KR20010077840A (ko) 2001-08-20
NO20003968D0 (no) 2000-08-04
AP2002002591A0 (en) 2002-09-30
TR200701171T2 (tr) 2007-04-24
SK11792000A3 (sk) 2001-12-03
EP2133070A1 (en) 2009-12-16
NO312434B1 (no) 2002-05-13
HU222578B1 (hu) 2003-08-28
AU5184100A (en) 2001-08-02
RS50201B (sr) 2009-07-15
CZ20002884A3 (cs) 2001-09-12
DK200001170A (da) 2001-01-27
YU52902A (sh) 2006-01-16
IL150513A (en) 2012-12-31
TR200200270T2 (tr) 2002-06-21
HK1047052A1 (zh) 2003-02-07
CA2313783C (en) 2002-03-12
CA2315141A1 (en) 2001-07-26
TR200201888T2 (tr) 2002-11-21
FI20001749A0 (fi) 2000-08-04
DE10038110A1 (de) 2001-08-23
JP2001206847A (ja) 2001-07-31
CR10114A (es) 2008-08-21
EE200200052A (et) 2003-04-15
KR20030036492A (ko) 2003-05-09
AT412063B (de) 2004-09-27
IS1940B (is) 2004-07-16
HU0003110D0 (en) 2000-10-28
JP3267960B2 (ja) 2002-03-25
AT412062B (de) 2004-09-27
TW553749B (en) 2003-09-21
AP1449A (en) 2005-07-28
HRP20080525A2 (en) 2008-12-31
GB0019029D0 (en) 2000-09-27
ES2155043A1 (es) 2001-04-16
HRP20020097A2 (en) 2002-06-30
AU2005202392A1 (en) 2005-06-30
PT102503A (pt) 2000-12-29
SE523471C2 (sv) 2004-04-20
ME00191B (me) 2010-10-10
RU2002122752A (ru) 2004-03-10
IS6480A (is) 2002-07-23
ME00202B (me) 2010-10-10
HUP0003111A3 (en) 2003-03-28
CH691347A5 (de) 2001-07-13
EE200900047A (et) 2011-04-15
EP2266540A1 (en) 2010-12-29
EP1223918B1 (en) 2003-02-05
NL1015859A1 (nl) 2001-07-27
AU781269C (en) 2006-11-30
ES2155043B1 (es) 2001-12-01
JP4800988B2 (ja) 2011-10-26
DE60001371T2 (de) 2004-01-22
KR100698333B1 (ko) 2007-03-23
EP1251831A1 (en) 2002-10-30
FI121365B (fi) 2010-10-29
SI1223918T1 (en) 2003-06-30
CZ298411B6 (cs) 2007-09-26
NO20071303L (no) 2001-07-27
CH700184B1 (de) 2010-07-15
CN1319396A (zh) 2001-10-31
FI121589B (fi) 2011-01-31
HK1048950A1 (zh) 2003-04-25
IL187416A0 (en) 2008-02-09
DE10038108A1 (de) 2001-08-02
EE05586B1 (et) 2012-10-15
NO327554B1 (no) 2009-08-10
DK1223918T3 (da) 2003-04-28
HK1200368A1 (en) 2015-08-07
FR2795324A1 (fr) 2000-12-29
BG110353A (en) 2009-09-30
DK178242B1 (da) 2015-09-28
TWI228050B (en) 2005-02-21
CN1282581A (zh) 2001-02-07
SE523481C2 (sv) 2004-04-20
MEP33708A (hr) 2010-10-10
HK1036935A1 (en) 2002-01-25
CZ20002883A3 (cs) 2000-10-11
FR2795324B1 (fr) 2002-05-17
ATA13602000A (de) 2004-02-15
BG66168B1 (bg) 2011-10-31
NO20003968L (no) 2001-07-27
UA77156C2 (en) 2006-11-15
HRP20020097B1 (hr) 2010-12-31

Similar Documents

Publication Publication Date Title
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
ITMI20010748A0 (it) Composizioni farmaceutiche
DK1524266T3 (da) Farmaceutisk sammensætning
FI20011478L (fi) Farmaseuttinen koostumus
NO20025450L (no) Ny farmasöytisk sammensetning
ATE303787T1 (de) Schergelzusammensetzungen
ITTO20010008A0 (it) Formulazione farmaceutica
PT1242087E (pt) Composicoes farmaceuticas
AR028197A1 (es) Composiciones antitranspirantes
NO20033556L (no) Farmasöytiske formuleringer
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
EE05020B1 (et) Glburiidi ravimkoostis
EE200300589A (et) Ravimkoostised
NO20026123L (no) Farmasöytiske sammensetninger
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
FI20022128L (fi) Farmaseuttinen koostumus
NO20031095L (no) Farmasoytiske sammensetninger
PT1239832E (pt) Composicoes farmaceuticas
DE60116858D1 (de) Zusammensetzung
MXPA03001857A (es) Composicones medicinales.
EE200200689A (et) Ravimkoostised
DE60135223D1 (de) Shampoozusammensetzungen
EP1413314A4 (en) MEDICAL COMPOSITIONS

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 121365

Country of ref document: FI

MA Patent expired